Cargando…
Why choose cyclosporin A as first-line therapy in COVID-19 pneumonia()
Autores principales: | Sanchez-Pernaute, Olga, Romero-Bueno, Fredeswinda I., Selva-O’Callaghan, Albert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555974/ https://www.ncbi.nlm.nih.gov/pubmed/34756322 http://dx.doi.org/10.1016/j.reumae.2020.03.005 |
Ejemplares similares
-
Why choose cyclosporin A as first-line therapy in COVID-19 pneumonia()
por: Sanchez-Pernaute, Olga, et al.
Publicado: (2021) -
Cyclosporine A and COVID19 – The COQUIMA cohort
por: Sánchez-Pernaute, Olga
Publicado: (2020) -
Pharmacologic Treatment of Anti-MDA5 Rapidly Progressive Interstitial Lung Disease
por: Selva-O’Callaghan, A., et al.
Publicado: (2021) -
Choosing the Correct Double-Lumen Tube: Why One Size Cannot Fit All Just Yet
por: Gangakhedkar, Gauri R.
Publicado: (2022) -
Fine-tuning characterization of patients with interstitial pneumonia and an underlying autoimmune disease in real-world practice: We get closer with Nailfold videocapillaroscopy
por: Romero-Bueno, Fredeswinda Isabel, et al.
Publicado: (2023)